Evaluation of the Efficacy of Rapamycin and a Dipeptidyl Peptidase-4 Inhibitor (Vildagliptin) in Improving Beta Cell Function in Type 1 Diabetes of Long Duration, a Perspective Randomized Study
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Sirolimus (Primary) ; Vildagliptin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms MONORAPA
- 02 Nov 2020 Status changed from recruiting to completed.
- 30 Oct 2020 Results published in the Journal of Clinical Endocrinology and Metabolism
- 07 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.